Stock EXEL EXELIXIS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Exelixis, Inc.

Equities

EXEL

US30161Q1040

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
23.7 USD +0.72% Intraday chart for Exelixis, Inc. +5.24% -1.21%
Apr. 12 North American Morning Briefing : Big Banks Kick -2- DJ
Apr. 11 Barclays Downgrades Exelixis to Equalweight From Overweight, Price Target is $25 MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the past twelve months, EPS forecast has been revised upwards.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
EXELIXIS, INC. Stock Exelixis, Inc.
-1.21% 6.99B
B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
B+
ARGENX SE Stock argenx SE
+1.69% 22.15B
B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
B+
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. EXEL Stock
  4. Ratings Exelixis, Inc.